BlackRock
ALGS icon

BlackRock’s Aligos Therapeutics ALGS Stock Holding History

BlackRock’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.9K Hold
13,040
– – ﹤0.01% 4968
2025
Q4 		$122K Hold
13,040
– – ﹤0.01% 4852
2025
Q3 		$128K Hold
13,040
– – ﹤0.01% 4780
2025
Q2 		$94K Hold
13,040
– – ﹤0.01% 4855
2025
Q1 		$108K Sell
13,040
-681
-5% -$14.9K ﹤0.01% 4751
2024
Q4 		$547K Buy
13,721
+4,654
+51% +$89.9K ﹤0.01% 4391
2024
Q3 		$78.5K Sell
9,067
-29
-0.3% -$361 ﹤0.01% 4720
2024
Q2 		$79.6K Sell
9,096
-3,054
-25% -$53.7K ﹤0.01% 4753
2024
Q1 		$298K Buy
12,150
+304
+3% +$6.05K ﹤0.01% 4504
2023
Q4 		$197K Sell
11,846
-32
-0.3% -$550 ﹤0.01% 4642
2023
Q3 		$222K Sell
11,878
-141
-1% -$3.13K ﹤0.01% 4649
2023
Q2 		$292K Sell
12,019
-285
-2% -$7.64K ﹤0.01% 4632
2023
Q1 		$269K Buy
12,304
+6
+0% +$229 ﹤0.01% 4700
2022
Q4 		$293K Sell
12,298
-8,404
-41% -$212K ﹤0.01% 4746
2022
Q3 		$569K Sell
20,702
-320
-2% -$10.6K ﹤0.01% 4682
2022
Q2 		$636K Sell
21,022
-43,019
-67% -$1.46M ﹤0.01% 4694
2022
Q1 		$3.44M Buy
64,041
+109
+0.2% +$8.73K ﹤0.01% 4146
2021
Q4 		$19M Buy
63,932
+14,350
+29% +$5.23M ﹤0.01% 3306
2021
Q3 		$19.2M Buy
49,582
+6,220
+14% +$2.46M ﹤0.01% 3305
2021
Q2 		$22.1M Buy
43,362
+15,527
+56% +$9.9M ﹤0.01% 3236
2021
Q1 		$15.8M Buy
27,835
+1,251
+5% +$833K ﹤0.01% 3308
2020
Q4 		$18.4M Buy
+26,584
New +$12.9M ﹤0.01% 3053

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock's ALGS Position: Q1 2026 in Review

BlackRock held its Aligos Therapeutics (ALGS) position steady in Q1 2026 at 13,040 shares worth $96.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4968.

BlackRock first reported a position in ALGS in Q4 2020 and has held it in 22 quarters since. The position peaked at $22.1M in Q2 2021. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • BlackRock held 13,040 shares of Aligos Therapeutics worth $96.9K as of Q1 2026.
  • BlackRock left its Aligos Therapeutics share count unchanged in Q1 2026.
  • Aligos Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4968 holding.
  • BlackRock first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • BlackRock's Aligos Therapeutics position peaked at $22.1M in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.